Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | NDAQ

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Biosergen AB Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.	Sweden	BIOSGN
Bio Solution Co.,Ltd. Develops cell therapies for degenerative diseases and supplies bio-lab reagents for R&D.	South Korea	086820
Biosynex European manufacturer of rapid diagnostic tests for professionals and consumer self-tests.	France	ALBIO
BIO-TECHNE Corp Develops reagents and instruments for life sciences research and clinical diagnostic markets.	United States of America	TECH
biote Corp. Trains practitioners in hormone optimization using bioidentical pellets and nutraceuticals.	United States of America	BTMD
Biotest AG Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.	Germany	BIO3
Biotika A.S. Biotech firm making penicillin & polymyxin B APIs for human/vet use, plus contract manufacturing.	Slovakia	BSL
Bioton S.A. Develops and manufactures recombinant human insulin for global diabetes care solutions.	Poland	BIO
BIOVENTIX PLC Develops high-affinity sheep monoclonal antibodies for global clinical diagnostic immunoassays.	United Kingdom	BVXP
Bioversys N Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.	Switzerland	BIOV